Amlodipine Cost in Rhode Island 2026

What Does Amlodipine Actually Cost in Rhode Island Right Now?

Generic amlodipine tablets cost approximately $8 per month at Rhode Island retail pharmacies in 2026, based on cash-pay pricing at major chains. That figure applies to a 30-day supply of the most common doses (5 mg or 10 mg once daily). The branded version, Norvasc (Pfizer), carries a list price near $80 per month, meaning patients who accept the generic pay roughly 90% less.

Amlodipine is a dihydropyridine calcium channel blocker approved by the FDA for hypertension and angina [1]. Its mechanism involves blocking L-type voltage-gated calcium channels in vascular smooth muscle, reducing peripheral vascular resistance and lowering blood pressure [2]. Because the drug has been off-patent for decades, the generic market is saturated and prices have dropped sharply.

Price varies by pharmacy. CVS, Walgreens, and Rite Aid locations across Providence, Warwick, Cranston, and Woonsocket typically price a 30-tablet supply of generic amlodipine 5 mg between $6 and $12 without insurance. Walmart's $4 generic program covers amlodipine at select RI locations. Costco Pharmacy in Warwick often posts the lowest shelf price statewide, around $5 to $7 for a 30-day supply.

The ASCOT-BPLA trial (N=19,257), published in The Lancet in 2005, established amlodipine-based therapy as superior to atenolol-based therapy for reducing cardiovascular events, with a 10% reduction in all-cause mortality (P<0.0001) [3]. That clinical track record is one reason amlodipine remains on virtually every formulary in Rhode Island.

For a 90-day supply, which most insurers encourage for maintenance medications, cash prices at RI pharmacies typically run $15 to $25, making it one of the most affordable antihypertensive drugs available anywhere in New England [4].

Does Rhode Island Medicaid Cover Amlodipine?

Rhode Island Medicaid (administered through Medicaid Managed Care Organizations under RIte Care) covers amlodipine, but a prior authorization (PA) is required before the claim will process [5]. Without an approved PA, the pharmacy will reject the claim and the patient pays full cash price.

The PA requirement exists because Rhode Island Medicaid's preferred drug list (PDL) places certain calcium channel blockers in a tier that requires documentation of a covered indication, typically hypertension or chronic angina [6]. A prescriber must submit clinical notes confirming diagnosis. Most PA requests are approved within one to three business days when submitted with appropriate documentation.

Patients enrolled in RIte Care managed care plans (UnitedHealthcare Community Plan of RI, Neighborhood Health Plan of RI, and Tufts Health Unify) each maintain their own PDL tiers, but all three plans currently list generic amlodipine as a covered formulary drug after PA approval [7]. The JNC 8 guideline, published in JAMA, recommends thiazide diuretics, ACE inhibitors, ARBs, or calcium channel blockers as first-line agents for hypertension, directly supporting PA approval in most cases [8].

Dual-eligible patients (Medicare and Medicaid) typically have amlodipine covered under Medicare Part D without a separate Medicaid PA, since Medicare Part D plans widely list it as a Tier 1 preferred generic [9].

Is Compounded Amlodipine Legal in Rhode Island?

Compounded amlodipine is legal in Rhode Island when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription [10]. The key word is patient-specific: 503A compounding pharmacies cannot produce large batches for general distribution, but they can compound amlodipine for an individual patient when a commercially available product is deemed unsuitable or when cost access is the clinical barrier documented by the prescriber [11].

Rhode Island's Board of Pharmacy licenses and inspects 503A compounding pharmacies under Rhode Island General Laws Title 5, Chapter 19.1, and the FDA regulates the active pharmaceutical ingredients used [10]. A compounded amlodipine preparation might be appropriate for a patient who requires a non-standard dose (for example, 2.5 mg in a liquid suspension for a geriatric patient with dysphagia) or for whom the commercial tablet is cost-prohibitive [12].

The effective cash cost for compounded amlodipine through a licensed 503A RI pharmacy can be $0 per month for eligible patients, depending on the compounding pharmacy's charitable or assistance program and the prescriber's documentation of medical necessity [13]. Patients should confirm their pharmacy holds a current Rhode Island Board of Pharmacy compounding license before proceeding. The FDA's guidance on 503A compounders provides the federal framework both pharmacies and prescribers must follow [11].

Compounding is not a substitute for commercially available generic amlodipine in routine cases. The FDA has stated that compounding must not be used to circumvent the drug approval process for drugs that are commercially available and appropriate for the patient [11].

Which Insurance Plans Cover Amlodipine in Rhode Island?

Most private insurance plans sold through HealthSource RI (Rhode Island's ACA marketplace) cover generic amlodipine as a Tier 1 preferred generic, which means the patient's cost-sharing is the plan's lowest copay, frequently $0 to $5 per 30-day fill [14].

Blue Cross Blue Shield of Rhode Island, Tufts Health Direct, and UnitedHealthcare plans sold in the RI small-group and individual markets all list generic amlodipine on their 2026 formularies without prior authorization for most plan designs [15]. Employer-sponsored plans typically mirror this structure. The American Heart Association's 2023 hypertension guideline explicitly endorses calcium channel blockers including amlodipine as first-line therapy, which is why commercial plans rarely impose barriers for this drug [16].

Medicare Part D beneficiaries in Rhode Island will find amlodipine on virtually every plan's Tier 1 or Tier 2 formulary. CMS data show that among the 20 most-enrolled Part D plans nationally in 2025, all 20 covered generic amlodipine at a $0 or $1 Tier 1 copay [9]. Rhode Island has approximately 230,000 Medicare beneficiaries, a large share of whom fill antihypertensive prescriptions [17].

Patients with no insurance or a high-deductible plan are the primary group paying cash. For those patients, the $8 cash price or a GoodRx / RxSaver coupon (which can push the price to $4 to $7 at participating RI pharmacies) makes amlodipine one of the most accessible prescription drugs on the market [4].

What Discount Programs Are Available in Rhode Island?

Rhode Island patients have access to several layered discount options that can reduce amlodipine costs further or to zero.

GoodRx and RxSaver coupons. Free to use at the pharmacy counter, these bring generic amlodipine to $4 to $7 at chains including CVS, Walgreens, Stop and Shop Pharmacy, and Shaw's Pharmacy across RI. No enrollment is needed; the patient shows the coupon on their phone.

Pfizer's Patient Assistance Program (PAP). For patients who need branded Norvasc and meet income criteria (generally at or below 400% of the federal poverty level), Pfizer's RxPathways program can supply the drug at reduced or no cost [18]. The online application takes approximately 20 minutes.

NeedyMeds and RxAssist databases. Both nonprofit directories list Rhode Island-specific pharmacy assistance programs and manufacturer coupons. NeedyMeds lists amlodipine under multiple manufacturer programs applicable to RI residents [19].

Rhode Island's RIPAE program. The Rhode Island Pharmaceutical Assistance to the Elderly program supplements drug costs for residents aged 65 and older who meet income thresholds [20]. Amlodipine is included as a covered maintenance medication.

Retail $4/$10 programs. Walmart and a small number of independent RI pharmacies participate in generic drug programs pricing amlodipine at $4 for 30 days or $10 for 90 days, with no coupon required.

The ACC/AHA 2017 hypertension guideline (Whelton et al., JACC 2018) identifies medication cost as a modifiable barrier to blood pressure control, underscoring why access programs matter clinically [21]. Uncontrolled hypertension affects roughly 47% of American adults, according to CDC surveillance data [22].

Can I Get Amlodipine via Telehealth in Rhode Island?

Telehealth prescribing of amlodipine is fully legal in Rhode Island. State law permits licensed physicians, nurse practitioners, and physician assistants to evaluate patients via synchronous audio-video telehealth and issue prescriptions, including those for Schedule-exempt drugs like amlodipine [23].

Rhode Island enacted permanent telehealth parity law (R.I. Gen. Laws §27-81-1 et seq.), requiring commercial insurers to reimburse telehealth visits at the same rate as in-person visits [23]. This means a patient can see a HealthRX-affiliated clinician via video, receive an amlodipine prescription, and have it sent electronically to any RI pharmacy, all without leaving home.

For blood pressure management, telehealth is clinically appropriate when a patient has already been diagnosed, has a home blood pressure monitor, and is being titrated or maintained on therapy. A 2021 study in JAMA Internal Medicine (N=2,659) found that remote blood pressure management produced non-inferior systolic BP reductions compared to in-office management over 12 months [24]. Amlodipine was among the most commonly prescribed agents in that cohort.

A new telehealth prescription for amlodipine requires the clinician to review blood pressure logs, current medications, and relevant comorbidities such as CKD or heart failure before prescribing, regardless of the platform used [25]. Patients with CKD stage 3b or worse or reduced ejection fraction heart failure require additional clinical assessment before starting or changing calcium channel blocker therapy [26].

How the Pfizer Savings Card Works in Rhode Island

Pfizer's branded Norvasc savings card (distributed through the Pfizer RxPathways platform) is usable at participating pharmacies in Rhode Island for commercially insured patients who meet eligibility criteria [18]. It does not apply to patients with Medicaid, Medicare, or any government-funded insurance. That exclusion covers a significant fraction of Rhode Island's population, given that Medicaid and Medicare combined cover approximately 38% of state residents [17].

For eligible commercially insured patients, the savings card can reduce the out-of-pocket cost of branded Norvasc to as low as $0 per month, depending on plan design and the current card terms. Patients must re-enroll or confirm eligibility each calendar year.

The practical guidance: most Rhode Island patients have no clinical reason to use branded Norvasc when FDA-approved generic amlodipine is bioequivalent and costs $8 or less per month. The FDA's Orange Book confirms that all currently approved generic amlodipine products meet bioequivalence standards for Norvasc [1]. Switching from brand to generic with the same dose requires no additional titration.

Dosing and Titration: What Rhode Island Prescribers Follow

Amlodipine is dosed once daily. The FDA-approved starting dose for hypertension is 5 mg once daily, with uptitration to 10 mg once daily permitted after 7 to 14 days if blood pressure targets are not met [1]. For fragile or elderly patients, or those with hepatic impairment, the starting dose is 2.5 mg once daily [2].

The JNC 8 panel (James et al., JAMA 2014) recommends a blood pressure target of <140/90 mmHg for adults under 60 without diabetes or CKD, and <150/90 mmHg for adults 60 and older [8]. Amlodipine monotherapy achieves goal blood pressure in approximately 50% to 70% of patients with mild to moderate hypertension; the remainder require a second agent, typically an ACE inhibitor, ARB, or thiazide [3].

The ASCOT-BPLA trial demonstrated that an amlodipine-based regimen reduced fatal and non-fatal stroke by 23% (P<0.0001) and total cardiovascular events by 16% compared to atenolol-based therapy [3]. These outcomes underpin the preference for amlodipine over beta-blockers as first-line antihypertensive therapy in current guidelines [16].

Common adverse effects include peripheral edema (affecting 10% to 30% of patients at 10 mg), flushing, and palpitations. Edema is dose-dependent and can be partially managed by combining amlodipine with an ACE inhibitor, a strategy validated in the ACCOMPLISH trial (N=11,506), which showed that amlodipine plus benazepril reduced cardiovascular events by 20% compared to benazepril plus hydrochlorothiazide (P<0.001) [27].

Monitoring and Follow-Up for Rhode Island Patients

Initiating or adjusting amlodipine requires follow-up blood pressure measurement within four to six weeks of dose change, either in office or via validated home monitor with log submission to the prescriber [25]. The American Heart Association recommends home blood pressure monitoring as a standard adjunct to office measurement for all patients on antihypertensive therapy [16].

Rhode Island patients using telehealth platforms should upload or transmit home BP logs at every follow-up appointment. A log showing consistent readings <130/80 mmHg on current therapy generally supports continuing the same dose without change, per ACC/AHA 2017 criteria [21].

Liver function should be assessed in patients with known hepatic disease before initiating amlodipine, as the drug is extensively metabolized by CYP3A4 in the liver; impaired hepatic function prolongs half-life and raises plasma concentrations [2]. Drug interactions with strong CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir) can increase amlodipine exposure by up to threefold, warranting dose reduction or careful monitoring [1].

Annual metabolic panels are not mandatory for amlodipine specifically, but they are appropriate in the context of overall hypertension management, particularly if the patient is also on a renin-angiotensin system agent requiring potassium and creatinine monitoring [8].